Latest Regulatory News

Estrella Resources has gained regulatory approval to extract a 30,000-tonne bulk sample of high-grade manganese from its Ira Miri project, marking a pioneering step for Timor-Leste’s mining sector under its modern Mining Code.

Critical Resources has engaged SLR Consulting to streamline permitting for its Mavis Lake Lithium Project in Ontario, aiming to fast-track approvals and secure government funding. This move strengthens the project’s role in North America’s lithium supply chain amid growing demand for sustainable battery materials.

Duratec Limited’s joint venture with Ertech has been greenlit to begin early procurement for critical infrastructure upgrades at HMAS Stirling, supporting Australia’s future submarine capabilities under the AUKUS partnership.

Lindian Resources reports strong construction progress at its Kangankunde Rare Earths Project in Malawi, highlighted by the arrival of its Komatsu owner-operator mining fleet and advancing infrastructure works.

West Coast Silver has completed a $3.2 million placement, issuing over 16.8 million shares, to advance its high-grade Elizabeth Hill silver project, a historically prolific mine with significant exploration upside in Western Australia.

Lunnon Metals has secured the last regulatory approval needed to advance its Lady Herial gold project, bringing it closer to production under a key agreement with St Ives Gold Mining.

BlackRock Investment Management (Australia) Limited has announced the final cash distributions for over 30 Australian domiciled iShares ETFs listed on the ASX and CBOE Australia, detailing payment schedules and reinvestment options.

Hydrix Limited’s subsidiary has landed a significant A$2.5 million contract to develop SynCardia’s next-generation fully implantable Total Artificial Heart, marking a major step in advanced cardiovascular technology.

Augustus Minerals has addressed ASX concerns over its recent appointment and election of a new director, clarifying compliance with listing rules despite timing challenges.

Neuren Pharmaceuticals has published promising Phase 2 trial results for NNZ-2591 in Phelan-McDermid syndrome, underpinning its ongoing Phase 3 Koala trial recruiting in the US.

CurveBeam AI has received official Chinese regulatory approval for a strategic $10 million investment from WEGO Orthopaedics, marking a major step in its expansion into Greater China. The initial $4 million tranche at a premium share price is expected imminently, underpinning a decade-long commercialisation deal.

Island Pharmaceuticals has been granted a key US patent for Galidesivir, extending intellectual property protection through 2031 for treating filoviridae viruses including Marburg and Ebola. This milestone aligns with the company’s clinical development strategy and recent FDA regulatory progress.